Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) was founded in 2005, formerly known as Lightlake Therapeutics Inc., changed to its current name in January 2016, headquartered in Santa Monica, California, USA, with 16 full-time employees, and a subsidiary of Pelikin Group , Focusing on the development of drug treatments for substance use, addiction and eating disorders.
Opiant Pharmaceuticals, Inc. (OPNT):
Opiant Pharmaceuticals is a specialty pharmaceutical company that provides NARCAN nasal spray, a treatment to reverse opioid overdose.
Opiant Pharmaceuticals’ product candidates include eating disorders, including bulimia nervosa and binge eating disorder, alcohol use disorder and other therapeutic drugs. Long-term treatment is used to prevent opioid use disorder, cocaine use disorder and heroin vaccine patients from relapse.
Opiant Pharmaceuticals, Inc. and Titan Pharmaceuticals, Inc. have reached a cooperation agreement to explore the development of a new method to prevent opioid recurrence and overdose in patients with opioid use disorder.